GSK plc - Company Profile
Powered by
All the data and insights you need on GSK plc in one report.
- Save hours of research time and resources with
our up-to-date GSK plc Strategy Report
- Understand GSK plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreGSK plc (GSK) is a healthcare company that focuses on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterial, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastrointestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
GSK plc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Specialty Medicines | Advair |
Vaccines | Coreg |
General Medicines | Epzicom |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In May, the company signed a memorandum of understanding with the Department of Health – Abu Dhabi to build a regional vaccine distribution hub in Abu Dhabi, the UAE. |
2024 | Contracts/Agreements | In May, the company announced an expanded partnership with BioVersys AG to accelerate the clinical development of alpibectir (BVL-GSK098) for treating tuberculosis. |
2024 | Regulatory Approval | In May, the company secured approval from the Health Sciences Authority of Singapore for Arexvy to prevent lower respiratory tract disease caused by respiratory syncytial virus. |
Competitor Comparison
Key Parameters | GSK plc | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc |
---|---|---|---|---|---|
Headquarters | United Kingdom | United States of America | Switzerland | United States of America | United States of America |
City | Brentford | New Brunswick | Basel | Rahway | New York |
State/Province | England | New Jersey | - | New Jersey | New York |
No. of Employees | 70,212 | 131,900 | 103,605 | 72,000 | 88,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Dame Emma Walmsley | Chief Executive Officer; Director | Executive Board | 2017 | 54 |
Julie Brown | Chief Financial Officer; Director | Executive Board | 2023 | 61 |
Diana Conrad | Chief People Officer | Senior Management | 2019 | - |
Tony Wood | Chief Scientific Officer | Senior Management | 2022 | - |
Luke Miels | Chief Commercial Officer | Senior Management | - | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer